Journal of Postgraduate Medicine, Education and Research

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  58 (2024)
Volume  57 (2023)
Volume  56 (2022)
Volume  55 (2021)
Volume  54 (2020)
Volume  53 (2019)
Volume  52 (2018)
Volume  51 (2017)
Volume  50 (2016)
Volume  49 (2015)
Volume  48 (2014)
Volume  47 (2013)
Volume  46 (2012)
Related articles

VOLUME 47 , ISSUE 1 ( January-March, 2013 ) > List of Articles

REVIEW ARTICLE

A Bridge not too Far: Personalized Medicine with the use of Theragnostic Radiopharmaceuticals

Suresh C Srivastava

Citation Information : Srivastava SC. A Bridge not too Far: Personalized Medicine with the use of Theragnostic Radiopharmaceuticals. J Postgrad Med Edu Res 2013; 47 (1):31-46.

DOI: 10.5005/jp-journals-10028-1054

Published Online: 01-12-2014

Copyright Statement:  Copyright © 2013; The Author(s).


Abstract

How to cite this article

Srivastava SC. A Bridge not too Far: Personalized Medicine with the use of Theragnostic Radiopharmaceuticals. J Postgrad Med Edu Res 2013;47(1):31-46.

PDF Share
  1. Paving the way to personalized medicine: Production of some promising theragnostic radionuclides at Brookhaven National Laboratory. Semin Nucl Med 2012;42: 151-63.
  2. Theragnostic radiopharmaceuticals: The ‘Janus’ approach to molecular diagnosis and therapy. CME session # 63 on Novel radiopharmaceuticals for molecular imaging and therapy–where are we headed next? Presented at 2009 SNM Annual Meeting, Toronto, Canada, June 15, 2009.
  3. Theragnostic radiometals: Getting closer to personalized medicine. In: Mazzi U, et al (Eds). Technetium and other radiometals in chemistry and nuclear medicine. Padova, Italy, SG Editorial 2010;553-68.
  4. Paving the way to personalized medicine: Production of some theragnostic radionuclides at Brookhaven National Laboratory. Radiochim Acta 2011;99:635-40.
  5. Measurement of pharmacokinetics of yttrium-86 radiopharmaceuticals with PET and radiation dose calculation of analogous yttrium-90 radiotherapeutics. J Nucl Med 1993;34:2222-36.
  6. Radiolabeled monoclonal antibodies for imaging and therapy. New York: Plenum Press 1988;876.
  7. Recent advances in radionuclide therapy. Seminars in Nucl Med 2001;31:330-41.
  8. Improved quality of life in patients treated with peptide radionuclides. World J Nucl Med 2011;10:115-21.
  9. Lethality of Auger electrons from the decay of Br-77 in the DNA of mammalian cells. Radiat Res 1982;90:362-73.
  10. Radiobiologic implications of the microscopic distribution of energy from radionuclides. Nucl Med Biol 1987;14:165-69.
  11. Biological damage from the Auger effect: Possible benefits. Radiat Environ Biophys 1975;12:85-99.
  12. Excitation functions of proton induced nuclear reactions on enriched 61Ni and 64Ni: Possibility of production of no-carrier-added 61Cu and 64Cu at a small cyclotron. Appl Radiat Isotopes 1993;44:575-80.
  13. Radiochemical studies relevant to Y-86 production via 86Sr(p, n)86Y for PET imaging. Appl Radiat Isot 2009;67:7-10.
  14. Irradiation of strontium chloride targets at proton energies above 35 MeV to produce PET radioisotope Y-86. Radiochim Acta 2011;99: 755-61.
  15. Evaluation of excitation functions of 3He and α-particle induced reactions on antimony isotopes with special relevance to the production of iodine-124. Appl Radiat Isotopes 2001;69:94-104.
  16. Chemical and biological evaluation of scandium (III)-polyamino-polycarboxylate complexes as potential PET agent and radiopharmaceutical. Radiochim Acta 2011;99:653-62.
  17. Production of high specific activity Ge-68 at Brookhaven National Laboratory. J Radioanal Nucl Chemistry 2005;263:553-57.
  18. Production and evaluation of Sc-47 for radioimmunotherapy. J Labelled Compds Radiopharm 1993;32:388-90.
  19. Radiochemical purification of no-carrier-added Scandium-47 for radioimmunotherapy. Appl Radiat Isot 1998;49:1541-49.
  20. Scandium 47: A replacement for Cu-67 in nuclear medicine therapy with beta/gamma emitters. In: Stevenson N (Eds). Isotope production and applications in the 21st Century. London: World Scientific 2000;43-45.
  21. Production of nocarrier-added Cu-67. Int J Radiat Appl Instrum Part A, Appl Radiat Isot 1986;37:29-36.
  22. Maximum tolerated dose of 67Cu-2IT-BAT-LYM-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: A pilot study. Anticancer Res 1998;18:2779-88.
  23. 67Cu-2IT-BATLym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphoma. J Nucl Med 1999; 40:302-10.
  24. Development of large scale production of Cu-67 from Zn-68 at the high energy accelerator: Closing the Zn-68 cycle. Int J Appl Radiat Isot 2012;70:423-29.
  25. Cancer therapy with alpha-emitters labeled peptides. Semin Nucl Med 2010;40:204-08.
  26. Targeted particle immunotherapy for myeloid leukemia. Blood 2002;100:1233
  27. Preclinical evaluation of the alpha-particle generator nuclide Ac-225 for somatostatin receptor radiotherapy of neuroendocrine tumors. Clin Cancer Res 2008;14:3555
  28. Evaluation of an internal cyclotron target for the production of 211At via the 209Bi (alpha, 2n)211 at reaction. Appl Radiat Isot 1996;47: 135-43.
  29. High-level production of alpha-particle-emitting (211)At and preparation of (211) At-labeled antibodies for clinical use. J Nucl Med 2001;42:1508-15.
  30. Comparative cellular catabolism and retention of astatine-, bismuth-, and lead-radiolabeled internalizing monoclonal antibody. J Nucl Med 2001;42:1538-44.
  31. The arronax project. Current Radiopharm 2011;4:186-96.
  32. An Ac-225/Bi-213 generator system for therapeutic clinical applications: Construction and operation. Applied Radiat Isot 1999;50:895
  33. Bi-213-DOTA(0), Tyr(3) octreotide peptide receptor radionuclide therapy of pancreatic tumors in a preclinical animal model. Clinical Cancer Res 2006;12:897
  34. The Feasibility of Ac-225 as a source of alpha-particles in radioimmunotherapy. Nucl Med Commun 1993;14:121
  35. Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applications. Advanced Drug Delivery Reviews 2008;60:1371
  36. Enhanced retention of the alpha-particle-emitting daughters of actinium-225 by liposome carriers. Bioconj Chem 2007;18:2061
  37. J. Radioanal Nucl Chem 2009;280:329
  38. Alpha-particle immunotherapy for acute myeloid leukemia (AML) with bismuth-213 and actinium-225. Cancer Biother Radiopharm 2006;21:40
  39. Production of actinium-225 for alpha particle mediated radioimmunotherapy. Appl Radiat Isot 2005;62:667
  40. Production of Ac-225 from Th-229 for targeted alpha therapy. Analytical Chem 2005;77:6288
  41. Production of 225Ac and 223Ra by irradiation of Th with accelerated protons. Radiochemistry 2011;53:73-80.
  42. Cyclotron and linac production of Ac-225. Appl. Radiat Isot 2009;67(4):549-55.
  43. Macrocyclic polyaminocarboxylates for radiometal antibody conjugates for therapy, SPECT and PET imaging. US Patent #5,639,879, June 17, 1997.
  44. Rigid bifunctional chelating agents. US Patent # 6,022,522, February 8, 2000.
  45. Nuclear data for production of 117mSn for biomedical application. In: Proceedings of the International Conference on Nuclear Data for Basic and Applied Science. Santa Fe: New Mexico 1985 May;733-37.
  46. Evaluation of neutron inelastic scattering for radioisotope production. Appl Radiat Isot 1997b;48:441-46.
  47. Reactor production of high-specific activity tin-117m for bone pain palliation and bone cancer therapy. J Nucl Med 2004;45:475
  48. Treatment of metastatic bone pain with tin-117m(4+)DTPA: A phase II clinical study. Clinical Cancer Res 1998;4:61-68.
  49. Production of no-carrier-added Tin-117m from proton irradiated antimony. J Radioanal Chem 2009;280:319-24.
  50. Production of carrier-free 117mSn. Int J Appl Radiat Isot 1984;35:645-50.
  51. Level and isomer systematics in even tin isotopes from Sn-108 to Sn-118 observed in Cd(α, xn) Sn reactions. Nucl Phys A 1969;134:81-109.
  52. Production of no-carrier-added Sn-117m at medium energy cyclotrons. Publication in Progress (2012).
  53. Marrow sparing effects of Sn-117m (4+) DTPA for radionuclide therapy of cancer in bone. J Nucl Med 2000;41:2043-50.
  54. The development and in vivo behavior of tin containing radiopharmaceuticals II: Autoradiographic and scintigraphic studies in normal animals and in animal models of bone disease. Int J Nucl Med Biol 1985;12:175-84.
  55. In vivo tissue uptake and retention of Sn-117m (4+) DTPA in a human subject with metastatic bone pain and in normal mice. Nucl Med Biol 1998;25:279-87.
  56. Intravascular stents electroplated with Sn-117m reduce arterial wall inflammation in hyperlipidemic rabbits. Atlanta, GA: Presented at the GLS 2007 Meeting, October 3, 2007 (abstr).
  57. Intravascular stents electroplated with 117mSn reduce arterial wall inflammation in hyperlipidemic rabbits. Chicago, IL: Presented at the 2008 ACC Annual Meeting, May, 2008 (abstr).
  58. Evaluation of tin-117m labeled Annexin V for imaging atherosclerotic lesions in a hyperlipidemic rabbit model. Publication in Progress (2013).
  59. Development and evaluation of tin-117m labeled Annexin for the imaging and treatment of vulnerable plaques. Publication in Progress (2013).
  60. Method of electroplating a conversion electron emitting source on implant. US Patent Application Serial No 11/758,914, Dec 22, 2011; Publication in Progress (2013).
  61. Theragnostic potential of Sn-117m for the molecular targeting and therapy of vulnerable plaque. Publication in Progress (2013).
  62. Therapeutic radionuclides: Making the right choice. In: Mather SJ (Eds). Current directions in radiopharmaceutical research and development. Dordrecht, The Netherlands: Kluwer Academic Publishers 1996;63-79.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.